2.3. Synergistic Interactions between Silibinin and Nintedanib in NSCLC Cells with Acquired Resistance to EGFR- and ALK-Tyrosine Kinase Inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.